** Shares of AI-enabled precision medicine firm Tempus AI TEM.O rise 3.7% to $53.85

** Co announces research collaboration with Angiosarcoma Awareness, a patient-driven charity focused on supporting patients and funding research for angiosarcoma

** Angiosarcoma is a rare and aggressive cancer that starts in cells lining blood vessels; about 1,000 people are diagnosed in the U.S. each year, co says

** Co says collaboration will use about 600 de-identified angiosarcoma records with DNA and RNA sequencing data, along with clinical information where available

** Says the dataset is one of the largest known molecular datasets for angiosarcoma and could help find disease patterns and potential treatment opportunities

** Including session's move, TEM down 7.6% YTD